ESLAW
Estrella Immunopharma, Inc.
Key Financials
Net Income
$-13063512
↓ 195.1%
Operating Income
$-13062674
↓ 195.1%
EPS (Diluted)
$-0.35
↓ 191.7%
Total Assets
$3.2M
↑ 1.2%
Total Liabilities
$13.5M
↑ 351.9%
Shareholders' Equity
$-10366058.00
↓ 7312.1%
Cash & Equivalents
$1.4M
↑ 51.0%
Operating Cash Flow
$-1785679.00
↑ 42.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ESLAW |
| Company Name | Estrella Immunopharma, Inc. |
| CIK | 1844417 |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | (510) 318-9098 |